Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients

Therapeutic Drug Monitoring

Volumn 27, Issue 4, 2005, Pages 431-434

  Armendáriz, Yolanda ^a   Pou, Leonor ^a,b   Cantarell, Carme ^a   Lopez, Rosa ^a   Perelló, Manuel ^a   Capdevila, Lluis ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

AUC; Sampling strategy; Tacrolimus

Indexed keywords

TACROLIMUS;

ACCURACY; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MODEL; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; SAMPLING; TIME TO REACH MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AREA UNDER CURVE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS;

EID: 23244454653     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000158080.61201.65     Document Type: Article

References (23)

1. Wallemacq PE, Reding R. FK 506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biochemical, and analytical aspects. Clin Chem. 1993;39:2219-2225.
2. Jiang H, Suguo H, Takahara S, et al. Combined immunosuppressive effect of FK506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. Transplant Proc. 1991;23:2933-2936.
3. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation. Transplantation. 1996;62:900-905.
4. Mc Master P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit. 1995;17:602-605.
5. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Clinical review. Drug Saf. 1995;12:348-357.
6. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998;44:381-387.
7. Winkler M, Ringe B, Christians U, et al. Therapeutic drug monitoring in patients under FK506 immunosuppression. Kin Lab. 1994;40:1-6.
8. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit. 1995;17:606-614.
9. Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999;21:1632-1652.
10. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
11. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients: correlation with toxicity. Transplant Proc. 1994;26:1804.
12. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205-218.
13. Primmet DRN, Levine M, Kovarik JM, et al. Cyclosporine monitoring in patients with renal transplants: two-or-three-points methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit. 1998;20:276-283.
14. Serafinowicz A, Gaciong Z, Baçzkowska T, et al. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with sandimmun-neoral. Transplant Proc. 1996;28:3138-3139.
15. Amante AJ, Kahan BD. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc. 1996;28:2162-2163.
16. Ritschell WA. Handbook of Basic Pharmacokinetics. 4th ed. Hamilton, IL: Drug Intelligence Publications, 1992, p 356-359.
17. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
18. Charlebois JE, Lum BL, Cooney GF, et al. Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatric renal transplant recipients. Ther Drug Monit. 1997;19:277-280.
19. Keown P, Kahan BD, Johnston A, et al. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the international Neoral® TDM advisory consensus meeting (Vancouver, November 1997). Transplant Proc. 1998;30:1645-1649.
20. Venkataramanan R, Lever J, Jain A, et al. FK506: correlation between trough concentrations and AUCs in transplant patients (abstract). Pharm Res. 1993;10:S390.
21. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57:281-290.
22. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35:660-666.
23. Ku YM, Min DI. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit. 1998;20:219-223.